🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Germany / NCT07464431
Recruiting Phase 4

Sodium Bicarbonate for Critically Ill Patients With Metabolic Acidosis and Acute Kidney Injury

NCT07464431 · tracked via the Priya Life Science Germany tracker
Phase
Phase 4
Started
2026-05-07
Last updated
2026-09-04

Condition(s) studied

Acute Kidney InjuryMetabolic AcidosisCritical Illness

Investigational drug(s) / intervention(s)

Sodium Bicarbonate 8.4% Solution for Injection →Balanced crystalloid solution

Sodium Bicarbonate 8.4% Solution for Injection: Intravenous infusion according to the treatment algorithm. Infusion starts with 100ml/hr until a pH of 7.30 - 7.35 and a Base Excess of ≥ 0 is reached. Then, infusion is reduced to 25ml/hr and maintained for 5 hours. After 5 hours, infusion is titrated to a pH of \>7.30.

Balanced crystalloid solution: Intravenous infusion according to the treatment algorithm. Infusion starts with 100ml/hr until a pH of 7.30 - 7.35 and a Base Excess of ≥ 0 is reached. Then, infusion is reduced to 25ml/hr and maintained for 5 hours. After 5 hours, infusion is titrated to a pH of \>7.30.

Study summary

The study investigates whether sodium bicarbonate is able to reduce the occurrence of major adverse kidney events on day 90 (MAKE90) in critically ill patients with metabolic acidosis and acute kidney injury (AKI). While its efficacy in this context has been suggested in a subgroup analysis of the BICAR-ICU trial it has not been confirmed in a double-blinded randomized controlled trial to date.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Adult ≥ 18 years 2. Critically ill patients (requiring treatment on an ICU or IMC) 3. Metabolic acidosis, defined as all of the following: 1. Arterial pH ≤7.25 2. PaCO2 \< 6.5kPa (\<49 mmHg) 3. Standard bicarbonate ≤20 mmol/L 4. Standard Base Excess \<-2 4. AKI stage 2 or 3 of the KDIGO classification 5. Written informed consent of the patient or legal representative or authorized representative or emergency inclusion (according to Article 35 EU-Regulation 536/2014) Exclusion Criteria: 1. Pregnant or breastfeeding patients 2. Respiratory acidosis (acute or chronic) \[dynamic, and if corrected, patient may be reconsidered for the trial\] 3. Patients on KRT, or KRT immediately indicated and treating clinician(s) unwilling to defer 4. Deemed unsuitable for KRT 5. High output stoma/ileostomy 6. Percutaneous biliary drainage 7. End stage kidney failure defined as documented eGFR \<15ml/min/1.73m 2 prior to onset of this acute illness or end stage kidney disease (ESKD) on dialysis 8. Known renal tubular acidosis 9. Diabetic ketoacidosis 10. High anion gap acid poisoning (e.g. polyethylene glycol (PEG), aspirin, methanol) 11. Symptomatic hypocalcaemia (Ionized calcium \<1.05 mmol/L)\[dynamic, and if corrected, patient may be reconsidered for the trial\] 12. Hypernatremia (plasma sodium \>150 mmol/L)\[dynamic, and if corrected, patient may be reconsidered for the trial\] 13. Severe hypokalemia (potassium \<3.0 mmol/L)\[dynamic, and if corrected, patient may be reconsidered for the trial\] 14. Death perceived as imminent 15. Known hypersensitivity to sodium bicarbonate or EDTA (Disodiumedetate) 16. Previously randomized into ESCALATE

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University Münster, University Hospital Münster Münster Germany Recruiting

More Universität Münster trials in Germany

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07464431 on ClinicalTrials.gov ↗ ← All trials in Germany